Achieve announces publication of the orca-1 phase 2b clinical trial of cytisinicline in adult smokers in nicotine and tobacco research

Cytisinicline up to five times more likely to result in smoking abstinence compared to placebo phase 3 orca-2 trial currently enrolling at 16 sites in united states seattle, wa and vancouver, bc / accesswire / april 14, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced publication of the results from the phase 2b orca-1 trial in the scientific journal nicotine and tobacco research. orca-1 evaluated the efficacy and safety of cytisinicline across various dosing and administration schedules in 254 smokers in the united states.
ACHV Ratings Summary
ACHV Quant Ranking